罗格列酮治疗深圳地区汉族人群不同脂联素基因型2型糖尿病患者的临床观察  

Clinical Observation of Rosiglitazone on Level with Type 2 Diabetes Mellitus Polymorphism of the APN Gene

作　　者：赵海燕[1] 田萍[1] 陈立波[1] 张长宁[1] 叶强[1] 张洪利[1] 

机构地区：[1]广东医学院附属南山医院内分泌科,广东深圳518052

出　　处：《中国药房》2013年第4期322-324,共3页China Pharmacy

基　　金：深圳市科技计划项目(No.200803186)

摘　　要：目的:观察罗格列酮治疗不同脂联素(APN)基因型的2型糖尿病患者的临床效果。方法:运用PCR-RFLP技术检测407例(136例非糖尿病者和271例2型糖尿病患者)深圳地区汉族APN基因SNP-11377C/G和-11391G/A变异情况,对其中150例2型糖尿病患者应用罗格列酮治疗12周。分析各位点与糖尿病的相关性,及用药前后血糖、血脂、胰岛功能及APN的变化情况。结果:深圳地区汉族人群APN基因SNP-11377C/G多态与糖尿病发病无显著相关,但CG+GG基因型APN浓度显著下降,HOMA-IR加重(P<0.05)。深圳地区汉族人群APN基因SNP-11391G/A多态与糖尿病发病可能相关,GA+AA基因型APN浓度显著下降,HOMA-IR加重(P<0.05)。结论:SNP-11377位点C/G变异可能影响罗格列酮的降糖效果,对药物敏感性CC型优于CG+GG型。OBJECTIVE：To observe the therapeutic efficacy of rosiglitazone in the treatment of type 2 diabetes mellitus of different adiponectin（APN）gene.METHODS：Variation of SNP-11377 C/G and SNP-11391 G/A in APN gene of 407 Han subjects（136 non-diabetes patients and 271 type 2 diabetes patients）from Shenzhen in China were detected by PCR-RFLP.150 type 2 diabetes patients were given rosiglitazone for 12 weeks.Correlation of gene locus with diabetes was analyzed,and the changes of blood glucose,blood lipid,islet function and change of APN were observed before and after medication.RESULTS：SNP-11377 C/G polymorphism was not associated with type 2 diabetes,and the level of mutant（CG ＋ GG）APN decreased significantly（P 0.05）.SNP-11391G/A may be related to type 2 diabetes,and the level of mutant（GA＋AA）APN decreased obviously（P0.05）.CONCLUSION：The variation of SNP-11377 C/G allele might affect the hypoglycemic effect of rosiglitazone,and CC gene are more sensitivity than CG＋GG.

关 键 词：APN 基因多态性 罗格列酮 临床观察 

分 类 号：R587.1[医药卫生—内分泌]